Abstract：
OBJECTIVE: The histrelin implant has been used to treat central precocious puberty (CPP) for more than 15 years. Although approved for annual use, limited published reports suggest that a single implant is efficacious well beyond a year. Our objective was to report our long-term experience using a single histrelin implant for more than 12 months in children with CPP.
METHODS: We performed a retrospective study of 170 children with central precocious puberty treated with a single histrelin implant for more than 1 year.
RESULTS: Implants were left in situ for an average of 24 months. Pubertal development regressed or remained stable in the vast majority of patients and biochemical suppression was maintained. No correlation between time since an implant was placed and complications such as implant breakage or a second incision was seen.
CONCLUSIONS: A single histrelin implant provides excellent pubertal suppression well beyond a year. Extended use of a single histrelin implant should be considered standard of care in children with CPP.
METHODS: We performed a retrospective study of 170 children with central precocious puberty treated with a single histrelin implant for more than 1 year.
RESULTS: Implants were left in situ for an average of 24 months. Pubertal development regressed or remained stable in the vast majority of patients and biochemical suppression was maintained. No correlation between time since an implant was placed and complications such as implant breakage or a second incision was seen.
CONCLUSIONS: A single histrelin implant provides excellent pubertal suppression well beyond a year. Extended use of a single histrelin implant should be considered standard of care in children with CPP.
摘要：
目的：histrelin植入物已用于治疗中枢性性早熟（CPP）超过15年。虽然批准每年使用，有限的已发表报告表明，单一植入物的疗效远远超过一年。我们的目标是报告我们在CPP儿童中使用单一histrelin植入物超过12个月的长期经验。
方法：我们对170例中枢性性早熟患儿进行了回顾性研究，这些患儿采用单一histrelin植入治疗超过1年。
结果：植入物在原位放置平均24个月。绝大多数患者的青春期发育消退或保持稳定，生化抑制得以维持。放置植入物的时间与植入物破裂或第二次切口等并发症之间没有相关性。
结论：一个单一的histrelin植入物提供了良好的青春期抑制超过一年。延长使用单一histrelin植入物应被视为CPP儿童的护理标准。
方法：我们对170例中枢性性早熟患儿进行了回顾性研究，这些患儿采用单一histrelin植入治疗超过1年。
结果：植入物在原位放置平均24个月。绝大多数患者的青春期发育消退或保持稳定，生化抑制得以维持。放置植入物的时间与植入物破裂或第二次切口等并发症之间没有相关性。
结论：一个单一的histrelin植入物提供了良好的青春期抑制超过一年。延长使用单一histrelin植入物应被视为CPP儿童的护理标准。
